Browsing Tag
JOURNAVX
2 posts
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Vertex secures FDA approval for non-opioid pain treatment JOURNAVX
Vertex Pharmaceuticals Incorporated has achieved a significant milestone in the field of pain management with the FDA approval…